

Effects of Cannabinoids on LPS-Stimulated Inflammatory Mediator Release From Macrophages: Involvement of Eicosanoids

Ying-Hsin Chang,¹ Sho Tone Lee,² and Wan-Wan Lin^{1*}

¹Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan

²Division of Infectious Diseases, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan

Abstract Δ^9 -Tetrahydrocannabinol (Δ^9 -THC) is the major psychoactive component of marijuana and elicits pharmacological actions via cannabinoid receptors. Anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG) are endogenous ligands for cannabinoid receptors, which because of their structural similarities to arachidonic acid (AA), AEA, and 2-AG could serve as substrates for lipoxygenases and cyclooxygenases (COXs) that metabolize polyunsaturated fatty acids to potent bioactive molecules. In this study, we have compared the effects of Δ^9 -THC, AEA, 2-AG, and another cannabinoid agonist, indomethacin morpholinylamide (IMMA), on lipopolysaccharide (LPS)-induced NO, IL-6, and PGE₂ release from J774 macrophages. Δ^9 -THC, IMMA, and AEA diminish LPS-induced NO and IL-6 production in a concentration-dependent manner. 2-AG inhibits the production of IL-6 but slightly increases iNOS-dependent NO production. Δ^9 -THC and IMMA also inhibit LPS-induced PGE₂ production and COX-2 induction, while AEA and 2-AG have no effects. These discrepant results of 2-AG on iNOS and COX-2 induction might be due to its bioactive metabolites, AA and PGE₂, whose incubation cause the potentiation of both iNOS and COX-2 induction. On the contrary, the AEA metabolite, PGE₂-ethanolamide, influences neither the LPS-induced NO nor IL-6 production. Taken together, direct cannabinoid receptor activation leads to anti-inflammatory action via inhibition of macrophage function. The endogenous cannabinoid, 2-AG, also serves as a substrate for COX-catalyzing PGE₂ production, which in turn modulates the action of CB2. *J. Cell. Biochem.* 81:715–723, 2001. © 2001 Wiley-Liss, Inc.

Key words: Δ^9 -THC; anandamide; immune suppression; endotoxin; macrophage

Δ^9 -Tetrahydrocannabinol (Δ^9 -THC) is the major psychoactive component of marijuana and has been used to alleviate the nausea associated with cancer chemotherapy, pain, migraine, epilepsy, glaucoma, hypertension, and AIDS wasting [Razdan, 1986; Annas, 1997]. Two G-protein-coupled receptors with seven transmembrane domains have been

identified as cannabinoid receptors and are referred to as CB1 and CB2 [Howlett, 1995; Adams and Martin, 1996; Felder and Glass, 1998]. CB1, initially designated the central cannabinoid receptor, is present in greatest abundance within the brain but is also present at low levels in peripheral tissues. CB2 is only present at the periphery and more particularly in cells of myeloid lineage. Both receptors are involved in mediating the diverse biological actions of cannabinoid compounds, including immune suppression via CB2 activation [Klein et al., 1998] and alterations in central nervous system function via CB1 activation [Herkenham et al., 1990; Abood and Martin, 1996]. To date, two types of arachidonic acid (AA)-containing molecules, anandamide and 2-arachidonoyl-glycerol (2-AG), have been reported to be endogenous ligands for the cannabinoid CB1 and CB2 receptors and to mediate the pleiotropic pharmacological effects as Δ^9 -THC [Felder and Glass, 1998].

Abbreviations used: AA, arachidonic acid; AEA, anandamide; 2-AG, 2-arachidonoyl-glycerol; COX-2, inducible COX; DMEM, Dulbecco's modified Eagle's medium; IL-6, interleukin-6; IMMA, indomethacin morpholinylamide; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; NO, nitric oxide; PCR, polymerase chain reaction; PGE₂, prostaglandin E₂; Δ^9 -THC, Δ^9 -tetrahydrocannabinol.

Grant sponsor: IBMS-CRC; Grant number: 88-T07.

*Correspondence to: Wan-Wan Lin, Ph.D., Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan. E-mail: wwl@ha.mc.ntu.edu.tw

Received 1 November 2000; Accepted 20 December 2000

© 2001 Wiley-Liss, Inc.

This article published online in Wiley InterScience, March 26, 2001.

Following reports indicating the wide distribution of AEA and 2AG, and their broad range of activity [Felder and Glass, 1998], the question arose as to whether both endogenous mediators exert their effects solely through the two cannabinoid receptors characterized so far. Indeed, cannabinoid receptor-independent effects of AEA have been suggested [Felder et al., 1993; Derocq et al., 1998]. Since AEA is a polyunsaturated fatty acyl amide with an unmodified arachidonate backbone, it is a substrate for the enzymes that metabolize AA and thereby plays a role as a precursor for other biologically active molecules. Recent *in vitro* studies have shown that AEA is a substrate for porcine leukocyte 12-lipoxygenase [Ueda et al., 1995], soybean 15-lipoxygenase [Hampson et al., 1995], rat brain 12-lipoxygenase [Hampson et al., 1995], and cyclooxygenase (COX) [Yu et al., 1997]. It was shown that in intact cells AEA was converted to 12(S)- and 15(S)-hydroxyarachidonylethanolamide by human polymorphonuclear leukocytes, and to 12(S)-hydroxyarachidonylethanolamide by human platelets [Edgmond et al., 1998]. Recently, several enzymes capable of hydrolyzing 2-AG to AA [Goparaju et al., 1998, 1999; Di Marzo et al., 1999], or to prostaglandin H₂ glycerol ester [Kozak et al., 2000] were also demonstrated. Currently the physiological significance of AEA and 2-AG metabolism by COX and/or lipoxygenases is not known.

Immune suppression is one of the major actions of cannabinoids, which are able to inhibit lymphocyte proliferation [Pross et al., 1992; Schwarz et al., 1994], antibody production, natural killer cell activity [Specter et al., 1980], and macrophage activity [Tang et al., 1992; Burnette-Curley et al., 1993; Friedman et al., 1994]. Consistent with these inhibitory features, cannabinoids are known to diminish general resistance to bacterial or viral infection [Morahan et al., 1979; Klein et al., 1994; Newton et al., 1994], and to suppress host immune reactivity against tumor growth [Zhu et al., 2000]. Among immune responses, macrophages play an essential role in local host defense against invading microorganisms. In response to foreign invaders and/or chemical signals generated by the affected tissues, macrophages recognize, phagocytose, and destroy the foreign agent. During the activation process, such as by treatment with the bacterial endotoxin, lipopolysaccharide (LPS), macrophages are a major

source releasing various inflammatory mediators which contribute to the local inflammatory response, including nitric oxide (NO), tumor necrosis factor- α , eicosanoid prostaglandin E₂ (PGE₂), and interleukin-6 (IL-6). Previous studies have provided evidence that the presence of CB2 receptors in macrophages [Jeon et al., 1996] underlies Δ^9 -THC inhibition of both iNOS induction [Coffey et al., 1996] and TNF- α production [Berdyshev et al., 1997]. Studies by Jeon et al. [1996] indicated that the inhibition of cAMP signaling is responsible for the inhibition of iNOS transcription and NO production by Δ^9 -THC. So far, although it was demonstrated that AEA and 2AG are synthesized from macrophages [Pestonjamas and Burstein, 1998; Varga et al., 1998; Di Marzo et al., 1999; Kozak et al., 2000], whether the two endogenous cannabinoids exhibit similar suppressive effects as that of Δ^9 -THC in macrophage activation is not yet established.

In this study we explore the pharmacological actions of cannabinoids in macrophage induction of NO, IL-6, and PGE₂. The possible involvement of eicosanoid metabolites in the actions of AEA and 2AG is considered.

MATERIALS AND METHODS

Cell Culture

The mouse J774 macrophage cell line was obtained from American Type Culture Collection and grown in DMEM containing 10% fetal bovine serum and antibiotics (100 U/ml penicillin and 100 μ g/ml streptomycin). Cells cultured at 37°C in a water-saturated atmosphere of 95% air and 5% CO₂ were seeded into 24-well plates for nitrite, PGE₂, and IL-6 assays and into 35-mm dishes for immunoblots.

Nitrite, PGE₂, and IL-6 Measurement

For inflammatory mediator induction, fresh culture medium containing LPS and/or indicated agonists, at the concentrations indicated, was added to cells, then the mediators released into the medium were measured 24 h later. Nitrite, an indicator of NO synthesis, was measured by adding 100 μ l of Griess reagent (1% sulfanilamide and 0.1% naphthylethylenediamide in 5% phosphoric acid) to 100- μ l samples of culture medium. Then the optical density at 550 nm (OD₅₅₀) was measured using a microplate reader, and the nitrite concentration was calculated by comparison with the

OD₅₅₀ produced using standard solutions of sodium nitrite in culture medium. PGE₂ and IL-6 were measured using enzyme immunoassay kits from Cayman, following the manufacturer's instruction.

Immunoblot Analysis

To quantify iNOS and COX-2 protein, cells were incubated for 24 h in the presence of various stimuli, after which they were washed twice in ice-cold phosphate-buffered saline, then solubilized in buffer containing 20 mM Tris-HCl, 0.5 mM EGTA, 2 mM EDTA, 2 mM dithiothreitol, 0.5 mM p-methylsulphonyl fluoride, and 10 µg/ml leupeptin (pH 7.5). Samples of equal amounts of protein (100 µg) were subjected to SDS-PAGE on 7.5% (iNOS) or 9% (COX-2) polyacrylamide gels, then transferred onto a nitrocellulose membrane, which was then incubated in 150 mM NaCl, 20 mM Tris, and 0.02% Tween (pH 7.4) containing 5% milk. The iNOS and COX-2 bands were visualized by immunoblotting with specific antibodies. Immunoreactivity was detected by enhanced chemiluminescence, following the manufacturer's instructions.

RNA Extraction and RT-PCR Analysis of IL-6 mRNA

Specific primers were synthesized to amplify murine macrophage IL-6 mRNA. The IL-6 primers used were: sense (277–294), 5'-TGC ACT TGC AGA AAA CAA TC-3' and antisense (607–624), 5'-TGG TCT TGG TCC TTA GCC-3'. β-Actin mRNA levels were used as internal controls. The β-actin primers used were: sense (613–632), 5'-GAC TAC CTC ATG AAG ATC CT-3' and antisense (1103–1122), 5'-CCA CAT CTG CTG GAA GGT GG-3'. After drug treatment, confluent cells were harvested. Total RNA was purified using the RNazol reagent, and RT-PCR was carried out using an RNA PCR kit, according to the manufacturer's instructions using 10 µg of total RNA as a template. Equal amounts (1 µg of cDNA) of each RT product were PCR-amplified with Taq polymerase in 30 cycles consisting of 40 sec at 95°C, 40 sec at 56°C, and 2 min at 72°C. The amplified cDNA was run on 1.2% agarose gels and visualized by ethidium bromide.

Materials

DMEM, fetal bovine serum, penicillin, streptomycin, Dulbecco's PBS (phosphate buffered

saline), and trypan blue dye were obtained from Gibco BRL (Grand Island, NY). Rabbit polyclonal antibodies specific for iNOS and COX-2 were respectively from Transduction Laboratories (Lexington, KY) and Santa Cruz Biotechnology (Santa Cruz, CA). Δ⁹-THC, AEA, and 2-AG were obtained from RBI (Natick, MA). IMMA, PGE₂ and IL-6 assay kits were obtained from Cayman Chemicals (Ann Arbor, MI). The RT-PCR kit was purchased from Stratagene (La Jolla, CA). Oligonucleotides were synthesized on a PS 250 CRUACHEM DNA synthesizer, using the cyanoethyl phosphoramidate method, and purified using gel filtration. Horseradish peroxidase-coupled anti-rabbit antibody and the enhanced chemiluminescence (ECL) detection agent were purchased from Amersham Pharmacia Biotech (Arlington Heights, IL). All materials for SDS-polyacrylamide gel electrophoresis (PAGE) were obtained from Bio-Rad Laboratories (Hercules, CA). All other chemicals were obtained from Sigma (St. Louis, MO).

Statistical Evaluation

Values are expressed as the mean ± standard error of the mean (SEM) of at least three experiments. Analysis of variance (ANOVA) was used to assess the statistical significance of the differences, and a *P* value of less than 0.05 was considered statistically significant.

RESULTS

Effects of Cannabinoids on LPS-Induced Mediator Release

Murine J774 macrophages were used to examine the effects on inflammatory mediator release of several cannabinoids, including Δ⁹-THC, AEA, 2-AG, and a CB2-preferring ligand, indomethacin morpholinylamide (IMMA) [Gallant et al., 1996]. In J774 macrophages, endotoxin LPS (1 µg/ml) stimulation leads to about 7- (from 6.1 ± 1 to 42 ± 5 µM), 6- (from 796 ± 280 to 4728 ± 991 pg/ml), and 7-fold (from 429 ± 104 to 3140 ± 500 pg/ml) increases in NO, IL-6, and PGE₂ release, respectively. Although these cannabinoids themselves cannot affect basal mediator release, co-incubation with LPS affects LPS responses in different ways. As shown in Figure 1A, 10 µM Δ⁹-THC co-addition with LPS (1 µg/ml) concentration-dependently reduced NO, IL-6, and PGE₂ release (Table I). Since Δ⁹-THC at 30 µM induced slight cytotoxicity,

TABLE I. Effects of Cannabinoids and Related Metabolites on LPS-Induced Nitrite, IL-6 and PGE₂ Release in J774 Macrophages

Treatment	% of LPS-induced response	
	Nitrite	IL-6
THC (10 μ M)	64 \pm 2%*	69 \pm 2%*
AEA (30 μ M)	61 \pm 4%*	62 \pm 5%*
2-AG (30 μ M)	117 \pm 2%*	56 \pm 1%*
IMMA (30 μ M)	64 \pm 3%*	51 \pm 4%*
PGE ₂ -ethanolamide (30 μ M)	92 \pm 5%	107 \pm 4%
AA (30 μ M)	172 \pm 17%*	56 \pm 16%*
PGE ₂ (1 μ M)	134 \pm 5%*	53 \pm 2%*

ND, not determined.

Each drug at indicated concentration was added with 10 μ g/ml LPS for 24 h. The data represent the mean \pm SEM from 3–5 independent experiments.

* $P < 0.05$ as compared to the response of LPS alone.

city as assessed by MTT test (50% \pm 3% inhibition of mitochondrial reductase activity after 24 h of treatment), we performed experiments with Δ^9 -THC using concentrations no greater than 10 μ M.

AEA at 3–30 μ M likewise attenuated the NO and IL-6 responses of LPS (Fig. 1B, Table I). Correspondingly, 2-AG at 3–30 μ M concentration-dependently reduced LPS-induced IL-6

release, while slightly increasing NO production by about 17% at 30 μ M (Fig. 1C, Table I). Since AEA and 2-AG are two AA analogues susceptible to COX-dependent metabolism and formation of PGE₂ mimetics, there is no rationale for measuring LPS-induced PGE₂ amounts by PGE₂ ELISA kits upon co-incubation of each cannabinoid with LPS. Like the effect of Δ^9 -THC, IMMA at 10 and 30 μ M concentration-dependently reduced NO and IL-6 responses of LPS (Fig. 1D, Table I).

Involvement of COX-Dependent Metabolites in Cannabinoid Actions

Since AEA can be metabolized by COX into PGE₂-ethanolamide [Yu et al., 1997] and 2-AG may generate AA [Di Marzo et al., 1999], it is crucial to explore the role that eicosanoids play in both cannabinoid effects. For this purpose, we first examined the effects of PGE₂-ethanolamide, PGE₂, and AA on LPS responses. We found that PGE₂-ethanolamide at 30 μ M could not alter the NO and IL-6 responses of LPS (Table I), while PGE₂ elicited opposite changes in both responses of LPS. At the concentration range of 0.1 nM to 1 μ M, PGE₂ concentration-dependently increased NO formation, but attenuated IL-6 release, in response to 1 μ g/ml LPS




Fig. 1. Effects of Δ^9 -THC, AEA, and 2-AG on LPS-induced nitrite, IL-6, and PGE₂ formation in J774 macrophages. Cells were treated with 1 μ g/ml LPS alone or with Δ^9 -THC (1–10 μ M) (A), AEA (3–30 μ M) (B), 2-AG (3–30 μ M) (C), or IMMA (D) for 24 h, then the amounts of nitrite, IL-6, and PGE₂ released into the medium were determined. LPS alone at 1 μ g/ml increased

nitrite, IL-6, and PGE₂ release from the basal level of 6 \pm 2 μ M, 693 \pm 190 pg/ml, and 402 \pm 118 pg/ml to 49 \pm 5 μ M, 5278 \pm 813 pg/ml and 3275 \pm 412 pg/ml, respectively. The data represent the mean \pm SEM of 3–7 experiments. * $P < 0.05$ indicates significant inhibition or potentiation of the LPS response.




Fig. 2. Effects of PGE₂ on LPS-induced nitrite and IL-6 formation in J774 macrophages. Cells were treated with 1 µg/ml LPS alone or with PGE₂ (0.1–1000 nM) for 24 h, and the amounts of nitrite and IL-6 released into the medium were determined. The control values for LPS-induced nitrite and IL-6 production, as indicated as the 100% response, were 43 ± 5 µM and 3827 ± 517 pg/ml, respectively. The data represent the mean ± SEM of 3–6 experiments. **P* < 0.05 as compared to the LPS response without PGE₂ treatment.

(Fig. 2, Table I). Consistent with the effects of PGE₂, AA at 30 µM increased NO release, but decreased IL-6 formation stimulated by LPS (Table I).

In considering that the actions of AA might be mediated by either a COX- or lipoxygenase-dependent process, we examined this issue from pharmacological approaches. As shown in Figure 3, pretreatment with either a non-selective COX inhibitor (3 µM indomethacin) or a COX-1 inhibitor (10 µM valeryl salicylate) both abrogated the effects of AA. Alternatively, the enhanced NO release and reduced IL-6 formation following AA co-incubation were mediated by the generation of COX-dependent metabolites. On the contrary, when the 5-lipoxygenase pathway was blocked by the 5-lipoxygenase-activating protein inhibitor, MK886 (10 µM), or the 12-lipoxygenase pathway was blocked by baicalein (10 µM), NO potentiation and IL-6 inhibition caused by AA was unaffected (Fig. 3). All these data suggest that a COX metabolite, possibly PGE₂, mediates the immunoregulatory action of AA in macrophages.

Effects of Cannabinoids on iNOS, COX-2, and IL-6 Expression

To confirm the inhibitory effects of cannabinoids on mediator release, we examined their effects on the expression of the inducible proteins, NOS, and COX-2, as well as on




Fig. 3. Effects of COX and lipoxygenase inhibitors on LPS/AA-induced nitrite and IL-6 formation in J774 macrophages. Cell were pretreated with inhibitors of COX (3 µM indomethacin and 10 µM valeryl salicylate) or lipoxygenase (10 µM MK 886 and 10 µM baicalein) for 30 min before the addition of 1 µg/ml LPS and 30 µM AA. The control values for LPS-induced nitrite and IL-6 production, as indicated as the 100% response, were 45 ± 4 µM and 4285 ± 612 pg/ml, respectively. The data represent the mean ± SEM of 3–5 independent experiments. **P* < 0.05 as compared to the AA response without drug pretreatment.

inducible IL-6 gene transcription. Immunoblot analysis revealed that Δ⁹-THC, AEA, and IMMA could inhibit LPS-mediated iNOS induction to 25% ± 8% (n = 3), 63% ± 4% (n = 3), and 43% ± 8% (n = 3) of the control, respectively, while 2-AG slightly enhanced iNOS immunoreactivity to 120% ± 4% (n = 3) of the control (Fig. 4). With respect to COX-2, Δ⁹-THC and IMMA could inhibit LPS-mediated COX-2 induction to 54% ± 6% (n = 3) and 79% ± 4% (n = 3) of the control, respectively, whereas AEA (93% ± 6% (n = 3) of the control) and 2-AG (110% ± 8% (n = 3) of the control) showed no significant changes (Fig. 4). RT-PCR analysis indicated that transcription of IL-6 mRNA could be induced after LPS stimulation for 4 h. Upon co-incubation with Δ⁹-THC, AEA, or 2-AG, this stimulated gene transcription was reduced, indicating that cannabinoids antagonize LPS-elicited IL-6 production through reducing IL-6 gene transcription.

To further characterize whether the non-significant inhibition of COX-2 induction by AEA and 2-AG results from the opposite effects caused by COX-dependent metabolites, we examined the effects of PGE₂, PGE₂-ethanolamide, and AA on COX-2 induction. As shown in




Fig. 4. Effects of cannabinoids on LPS-induced iNOS, COX-2, and IL-6 expression. Cells were treated with 1 μ g/ml LPS alone or in the presence of 10 μ M Δ^9 -THC, 30 μ M AEA, 10 μ M 2-AG, or 30 μ M IMMA for 24 h. In (A) and (B), whole cell lysates were prepared and subjected to Western blotting using antibodies specific for iNOS (A) or COX-2 (B) as described in "Methods". In (C), after 4 h of incubation with cannabinoids and LPS, RNA was extracted and analyzed for IL-6 expression by RT-PCR. To document equal amounts of the RNA and cDNA templates, the samples were also analyzed for β -actin. The results are representative of three independent experiments. Numbers in parentheses indicate the percentage change of iNOS, COX-2, or IL-6 after cannabinoid treatment.

Figure 5A, PGE₂, but not PGE₂-ethanolamide, incubation for 12 h increased COX-2 expression in a concentration-dependent manner. Likely, AA at 10 μ M also induced COX-2, and this effect was abolished by pretreatment with the specific COX-1 inhibitor, valeryl salicylate, but not by MK886, baicalein, or NDGA (a non-selective lipoxygenase inhibitor).

DISCUSSION

Many previous reports have shown that cannabinoids possess immunosuppressive effects. Cannabinoids diminish general resistance to bacterial or viral infection [Morahan et al., 1979; Klein et al., 1994; Newton et al., 1994], lymphocyte proliferation, antibody pro-




Fig. 5. Up-regulation of COX-2 expression by PGE₂ and AA. Cells were treated with PGE₂ at different concentrations, with 3 μ M PGE₂-ethanolamide, or with 10 μ M AA for 12 h, then the immunoreactivity of COX-2 was determined. In some experiments, cells were pretreated with valeryl salicylate, MK886, baicalein, or NDGA, each at 10 μ M for 30 min, before stimulation with AA. The results are representative of 3–5 independent experiments. Numbers in parentheses indicate the percentage change of COX-2 after inhibitor treatment.

duction, natural killer cell activity, and macrophage activity [Friedman et al., 1994]. At the molecular level, such modulation is expressed by the inhibition of the production of cytokines such as interferon [Blanchard et al., 1986], TNF- α [Zheng and Specter, 1996], and IL-2 [Nakano et al., 1992]. In addition, other studies indicated that Δ^9 -THC could inhibit LPS-induced nitrite production in mouse peritoneal macrophages [Coffey et al., 1996]. In human blood monocytes, Δ^9 -THC at low concentrations inhibits TNF- α , IL-6, and IL-8 production, while potentiating these mediators at high concentrations [Berdyshev et al., 1997]. Not only was anti-inflammation action seen for Δ^9 -THC, but the endogenous cannabinoid, AEA, was also shown to regulate nitrite release through activation of cNOS and by affecting iNOS expression in endothelial cells [Stefano et al., 1998], and by inhibiting IL-4, IL-6, IL-8, TNF- α , and IFN- γ production in human blood monocytes [Berdyshev et al., 1997].

Based on all the immunoregulatory actions of cannabinoids previously reported, we herein further delineated and compared the actions of four cannabinoid agonists on macrophage release of NO, PGE₂, and IL-6 in response to LPS. We chose murine J774 macrophages as the target cell system, as the murine macrophage

cell line has been shown to express CB2 [Jeon et al., 1996]. All three mediators are known to be induced through transcriptional signaling pathways and to play crucial roles in immunomodulation and inflammation responses upon exposure to endotoxin and many inflammatory insults [Grimble, 1990, Graeve et al., 1993]. Our results showed that Δ^9 -THC, mimicking its inhibitory actions on the release of other cytokines as previously observed, is capable of reducing LPS-elicited iNOS, COX-2 protein induction, and IL-6 gene transcription, which thereby lead to the attenuation of NO, PGE₂, and IL-6 production. Interestingly, we found that although these concentration-dependent inhibitory actions of Δ^9 -THC are mimicked by the synthetic cannabinoid agonist, IMMA, they cannot be completely mimicked by the two endogenous cannabinoids, AEA and 2-AG. With respect to IL-6 production, all cannabinoids examined, without exception, concentration-dependently produced inhibitory action. Regarding iNOS-related NO production, Δ^9 -THC, AEA, and IMMA caused inhibition, while a slight enhancement was observed for 2-AG. In contrast to the inhibition of COX-2 induction by Δ^9 -THC, AEA, and 2-AG did not elicit a similar effect.

The distinct effects of AEA and 2-AG as compared to those of Δ^9 -THC and IMMA might depend on their structural similarity to AA, which provides their susceptibilities for eicosanoid enzyme metabolism and produces pharmacological actions through eicosanoid receptor interaction. Indeed, accumulating studies have identified some bioactive metabolites of AEA and 2-AG in different cell types. AEA can be metabolized to many products, such as PGE₂-ethanolamide, 12(S)-HAEA, and 15(S)-HAEA, through many enzymes [Yu et al., 1997; Edmond et al., 1998]. 2-AG also can rapidly be metabolized to AA [Goparaju et al., 1998, 1999; Di Marzo et al., 1999], which is further converted to PGE₂ through COX, or to HPETE(s) and leukotrienes by lipoxygenase [Di Marzo et al., 1999]. In this study, pharmacological evidence supports the notion that AA and its downstream COX, but not lipoxygenase, metabolites participate in the actions of 2-AG. First, the iNOS-dependent NO potentiation induced by 2-AG was mimicked by exogenous AA and PGE₂. This study supports our previous report demonstrating that PGE₂ is able to potentiate LPS-elicited macrophage iNOS induction

through a PKA-dependent mechanism [Lin et al., 1999]. Second, the lack of inhibition by 2-AG on COX-2 induction, as contrasted with the ability of Δ^9 -THC and IMMA to do so, might be explained by the enhancement ability of AA and PGE₂ on COX-2 induction, which counteracts the inhibitory outcome ascribed from CB2 activation. Third, iNOS potentiation and IL-6 inhibition elicited by exogenous AA co-incubation were abolished by the presence of the COX-1 inhibitor, valeryl salicylate, instead of the lipoxygenase inhibitors, MK886, baicalein, and NDGA. Our present data do not seem to support the possible involvement of the metabolite, PGE₂-ethandamide, in AEA action, because exogenous PGE₂-ethandamide did not affect NO or IL-6 production by LPS. Nonetheless, at present, we still cannot explain the ineffectiveness of AEA on LPS-induced iNOS induction and NO production. We can not rule out whether other unidentified mechanisms or metabolites underlie the cumulative effects of AEA.

In summary, cannabinoids mediate the inhibition of LPS-induced NO, PGE₂, and IL-6 release in J774 macrophages through CB2 activation. In addition to acting as a CB2 activator, endogenous cannabinoid 2-AG itself serves as the AA precursor, whose metabolism by COX and generation of PGE₂ participates in the positive modulation of iNOS and COX-2 induction.

REFERENCES

- Abood ME, Martin BR. 1996. Molecular neurobiology of the cannabinoid receptor. *Int Rev Neurobiol* 39:197–221.
- Adams IB, Martin BR. 1996. Cannabis: pharmacology and toxicology in animals and humans. *Addiction* 91:1585–1614.
- Annas GJ. 1997. Reefer madness: the federal response to California's medical marijuana law. *N Engl J Med* 337:435–439.
- Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V. 1997. Influence of fatty acid ethanolamides and Δ^9 -tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. *Eu J Pharmacol* 330: 231–240.
- Blanchard DK, Newton C, Klein TW, Stewart WE 2d, Friedman H. 1986. In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. *Int J Immunopharmacol* 8:819–824.
- Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA. 1993. Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of *Bacillus Calmette-Guerin*-activated macrophages. *Int J Immunopharmacol* 15:371–382.

- Coffey RG, Yamamoto Y, Snella E, Pross S. 1996. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. *Biochem Pharmacol* 52:743–751.
- Deroq JM, Bouaboula M, Marchand J, Rinaldi-Carmona M, Casellas SP. 1998. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. *FEBS Lett* 425:419–425.
- Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G. 1999. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. *Eur J Biochem* 264:258–267.
- Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB. 1998. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. *Mol Pharmacol* 54:180–188.
- Felder CC, Briley EM, Axelrod J, Simpson J, Mackie K, Devance W. 1993. Anandamide, an endogenous cannabinoid eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor mediated signal transduction. *Proc Natl Acad Sci USA* 90:7656–7660.
- Felder CC, Glass M. 1998. Cannabinoid receptors and their endogenous agonists. *Annu Rev Pharmacol Toxicol* 38:179–200.
- Friedman H, Shivers S, Klein TW. 1994. Drugs of abuse and the immune system. In: Dean J, Luster M, Munson A, Kimber I, editors. *Immunotoxicology and immunopharmacology*. 2nd ed. New York: Raven Press. p 303–322.
- Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, Rochette C, Sawyer N, Slipetz DM, Tremblay N, Metters KM, Labelle M. 1996. New class of potent ligands for the human peripheral cannabinoid receptor. *Bioorg Med Chem Lett* 6:2263–2268.
- Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. 1998. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. *FEBS Lett* 422:69–73.
- Goparaju SK, Ueda N, Taniguchi K, Yamamoto S. 1999. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. *Biochem Pharmacol* 57:417–423.
- Graeve L, Baumann M, Heinrich PC. 1993. Interleukin-6 in autoimmune diseases. *Clin Invest* 71:664–671.
- Grimble RF. 1990. Nutrition and cytokine action. *Nutr Res Rev* 3:193–210.
- Hampson AJ, Hil WAG, Zan-Phillips M, Makriyannis A, Leung E, Egien RM, Bornheim LM. 1995. Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. *Biochem Biophys Acta* 1259:173–179.
- Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1990. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci USA* 87:1932–1936.
- Howlett A. 1995. Pharmacology of cannabinoid receptors. *Ann Rev Pharmacol Toxicol* 35:607–634.
- Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. 1996. Attenuation of inducible nitric oxide synthase gene expression by Δ^9 -tetrahydrocannabinol is mediated through the inhibition of nuclear factor- κ B/Rel activation. *Mol Pharmacol* 50:334–341.
- Klein TW, Newton C, Friedman H. 1994. Resistance to *Legionella-pneumophila* suppressed by the marijuana component, tetrahydrocannabinol. *J Infect Dis* 169:1177–1179.
- Klein TW, Friedman H, Specter S. 1998. Marijuana, immunity and infection. *J Neuroimmunol* 83:102–105.
- Kozak KR, Rowlinson SW, Marnett LJ. 2000. Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. *J Biol Chem* 275:33744–33749.
- Lin WW, Chen BC, Hsu YW, Lee CM, Shyue SK. 1999. Modulation of iNOS induction by PGE₂ in macrophages: distinct susceptibility in murine J774 and RAW 264.7 macrophages. *Prost Lipid Med* 58:87–101.
- Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE. 1979. Effects of cannabinoids on host resistance to *Listeria monocytogenes* and herpes simplex virus. *Infect Immun* 23:670–674.
- Nakano Y, Pross SH, Friedman H. 1992. Modulation of interleukin 2 activity by delta 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. *Proc Soc Exp Biol Med* 201:165–168.
- Newton CA, Klein TW, Friedman H. 1994. Secondary immunity to *Legionella-pneumophila* and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. *Infect Immun* 62:4015–4020.
- Pestonjamas V, Burstein SH. 1998. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. *Biochim Biophys Acta* 1394:249–260.
- Pross S, Nakano Y, Smith J, Widen R, Rodriguez R, Newton C, Friedman H. 1992. Suppressive effect of tetrahydrocannabinol on specific T cell subpopulations in the thymus. *Thymus* 19:97–104.
- Razdan RK. 1986. Structure-activity relationships in cannabinoids. *Pharmacol Rev* 38:75–149.
- Schwarz H, Blanco FJ, Lotz M. 1994. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte-proliferation and induces apoptosis. *J Neuroimmunol* 55:107–115.
- Specter S, Rivenbark M, Newton C, Kawakami Y, Lancz G. 1980. Prevention and reversal of delta-9-tetrahydrocannabinol-induced depression of natural killer cell activity by interleukin-2. *Int J Immun* 11:63–68.
- Stefano GB, Salzet M, Magazine HI, Bilfinger TV. 1998. Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. *J Cardio Pharmacol* 31:813–820.
- Tang JL, Lancz G, Specter S, Bullock H. 1992. Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. *Int J Immun* 14:253–262.
- Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, Ogawa M, Sato T, Kudo I, Inoue K, Takizawa H, Nagano T, Kirobe M, Matsuki N, Saito H. 1995. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. *Biochem Biophys Acta* 1254:127–134.
- Varga K, Wagner JA, Bridgen T, Kunos G. 1998. Platelet- and macrophage-derived endogenous cannabinoids are

- involved in endotoxin-induced hypotension. *FASEB J* 12:1035–1044.
- Yu M, Ives D, Ramesha CS. 1997. Synthesis of prostaglandin E₂ ethanolamide from anandamide by cyclooxygenase-2. *J Biol Chem* 272:21181–21186.
- Zheng ZM, Specter SC. 1996. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. *Int J Immun* 18:53–68.
- Zhu LX, Sharma S, Stolina M, Gardmer B, Roth MD, Tashkin DP, Dubinett SM. 2000. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. *J Immunol* 165:373–380.